JP2011527565A - 乳癌のリスクアセスメントのための遺伝的変異 - Google Patents

乳癌のリスクアセスメントのための遺伝的変異 Download PDF

Info

Publication number
JP2011527565A
JP2011527565A JP2011517318A JP2011517318A JP2011527565A JP 2011527565 A JP2011527565 A JP 2011527565A JP 2011517318 A JP2011517318 A JP 2011517318A JP 2011517318 A JP2011517318 A JP 2011517318A JP 2011527565 A JP2011527565 A JP 2011527565A
Authority
JP
Japan
Prior art keywords
seq
breast cancer
allele
individual
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011517318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011527565A5 (enExample
Inventor
サイモン ステイシー
パトリック スレム
Original Assignee
ディコーデ ジェネテクス イーエイチエフ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディコーデ ジェネテクス イーエイチエフ filed Critical ディコーデ ジェネテクス イーエイチエフ
Publication of JP2011527565A publication Critical patent/JP2011527565A/ja
Publication of JP2011527565A5 publication Critical patent/JP2011527565A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Library & Information Science (AREA)
  • Computing Systems (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2011517318A 2008-07-07 2009-07-03 乳癌のリスクアセスメントのための遺伝的変異 Pending JP2011527565A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS8746 2008-07-07
IS8746 2008-07-07
PCT/IS2009/000008 WO2010004591A2 (en) 2008-07-07 2009-07-03 Genetic variants for breast cancer risk assessment

Publications (2)

Publication Number Publication Date
JP2011527565A true JP2011527565A (ja) 2011-11-04
JP2011527565A5 JP2011527565A5 (enExample) 2012-08-16

Family

ID=41110719

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011517318A Pending JP2011527565A (ja) 2008-07-07 2009-07-03 乳癌のリスクアセスメントのための遺伝的変異

Country Status (10)

Country Link
US (1) US8951735B2 (enExample)
EP (1) EP2313525A2 (enExample)
JP (1) JP2011527565A (enExample)
KR (1) KR20110036608A (enExample)
CN (1) CN102144036B (enExample)
AU (1) AU2009269542A1 (enExample)
CA (1) CA2729934A1 (enExample)
IL (1) IL210504A0 (enExample)
NZ (1) NZ590833A (enExample)
WO (1) WO2010004591A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011095999A1 (en) * 2010-02-05 2011-08-11 Decode Genetics Ehf Genetic variants for predicting risk of breast cancer
EP2721180A4 (en) * 2011-06-16 2015-09-02 Decode Genetics Ehf GENETIC VARIANTS FOR PREDICTING THE RISK OF BREAST CANCER
CN102643905B (zh) * 2012-04-01 2014-06-11 周宏灏 焦磷酸测序法检测他莫昔芬个体化用药基因多态性的试剂盒及方法
KR101770962B1 (ko) * 2013-02-01 2017-08-24 에스케이텔레콤 주식회사 유전자 서열 기반 개인 마커에 관한 정보를 제공하는 방법 및 이를 이용한 장치
WO2014119914A1 (ko) * 2013-02-01 2014-08-07 에스케이텔레콤 주식회사 유전자 서열 기반 개인 마커에 관한 정보를 제공하는 방법 및 이를 이용한 장치
WO2014145705A2 (en) 2013-03-15 2014-09-18 Battelle Memorial Institute Progression analytics system
CN103981273B (zh) * 2014-05-30 2017-01-18 复旦大学附属肿瘤医院 一组评估乳腺癌风险的突变基因群及其检测试剂盒
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
CN105069322B (zh) * 2015-07-24 2018-01-12 上海尔云信息科技有限公司 疾病易感风险预测装置
CN109074426B (zh) 2016-02-12 2022-07-26 瑞泽恩制药公司 用于检测异常核型的方法和系统
CN105586427B (zh) * 2016-03-10 2020-06-19 厦门艾德生物医药科技股份有限公司 检测人类brca1和brca2基因突变的引物、试剂盒及方法
US11332530B2 (en) 2016-09-23 2022-05-17 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
CN106676169B (zh) * 2016-11-15 2021-01-12 上海派森诺医学检验所有限公司 一种用于乳腺癌易感基因brca1和brca2突变检测的杂交捕获试剂盒及其方法
CA3051488A1 (en) * 2017-01-24 2018-08-02 Genetic Technologies Limited Improved methods for assessing risk of developing breast cancer
CN107341347A (zh) * 2017-06-27 2017-11-10 天方创新（北京）信息技术有限公司 基于评分模型对乳腺癌进行风险评分的方法及装置
EP3814521A4 (en) * 2018-06-29 2022-07-27 The Jackson Laboratory SPLICING VARIANTS FOR BREAST CANCER
CN108676890B (zh) * 2018-07-12 2022-01-28 吉林大学 一种女性乳腺恶性肿瘤易感性预测试剂盒及系统
US20230170045A1 (en) * 2020-04-20 2023-06-01 Myriad Genetics, Inc. Comprehensive polygenic risk prediction for breast cancer
WO2024085660A1 (ko) * 2022-10-18 2024-04-25 제노플랜 인크 질병 발생 위험도 예측 장치 및 방법
WO2024148280A1 (en) 2023-01-06 2024-07-11 Ideaya Biosciences, Inc. Treatment of er+ breast cancer comprising homologous recombination deficiency using parc inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009481A1 (en) * 2001-06-11 2004-01-15 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
WO2008050356A1 (en) * 2006-10-27 2008-05-02 Decode Genetics Cancer susceptibility variants on chr8q24.21

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US6054270A (en) 1988-05-03 2000-04-25 Oxford Gene Technology Limited Analying polynucleotide sequences
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US6287850B1 (en) 1995-06-07 2001-09-11 Affymetrix, Inc. Bioarray chip reaction apparatus and its manufacture
EP0695941B1 (en) 1994-06-08 2002-07-31 Affymetrix, Inc. Method and apparatus for packaging a chip
US6300063B1 (en) 1995-11-29 2001-10-09 Affymetrix, Inc. Polymorphism detection
EP2369007B1 (en) 1996-05-29 2015-07-29 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US6429027B1 (en) 1998-12-28 2002-08-06 Illumina, Inc. Composite arrays utilizing microspheres
DE10228081A1 (de) * 2002-06-18 2004-01-08 InViTek Gesellschaft für Biotechnik & Biodesign mbH Verfahren zum Nachweis einer gesteigerten Tumorsuszeptibilität
KR100763902B1 (ko) * 2004-02-20 2007-10-05 삼성전자주식회사 유방암 특이적 단백질, 그를 코딩하는 유전자, 및 상기단백질 또는 유전자를 이용한 유방암의 진단 방법
WO2006063285A2 (en) * 2004-12-10 2006-06-15 Sequenom, Inc. Methods for identifying risk of breast cancer or prostate cancer and treatments thereof
CN101037690B (zh) * 2006-03-16 2011-07-20 国家人口计生委科学技术研究所 具有新的单核苷酸多态性的brca1基因变体和其编码的蛋白质变体
CN101874120B (zh) 2007-03-26 2015-01-14 解码遗传学私营有限责任公司 作为用于乳腺癌风险评估、诊断、预后和治疗的标记的chr2和chr16的遗传性变型
EP2164984A2 (en) 2007-05-25 2010-03-24 Decode Genetics EHF. Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009481A1 (en) * 2001-06-11 2004-01-15 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
WO2008050356A1 (en) * 2006-10-27 2008-05-02 Decode Genetics Cancer susceptibility variants on chr8q24.21

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
GOLD BERT ET AL: "GENOME-WIDE ASSOCIATION STUDY PROVIDES EVIDENCE FOR A BREAST CANCER RISK LOCUS AT 6Q22.33", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 105, no. 11, JPN5011006575, 1 March 2008 (2008-03-01), US, pages 4340 - 4345, XP002527419, ISSN: 0002728398, DOI: 10.1073/PNAS.0800441105 *
HOYAL CAROLYN R ET AL: "GENETIC POLYMORPHISMS IN DPF3 ASSOCIATED WITH RISK OF BREAST CANCER AND LYMPH NODE METASTASES", JOURNAL OF CARCINOGENESIS, vol. 4, no. 1, JPN5011006573, 19 August 2005 (2005-08-19), GB, XP021008706, ISSN: 0002728396, DOI: 10.1186/1477-3163-4-13 *
INGRAHAM ET AL, CANCER GENET CYTOGENET, vol. 115, JPN6014001916, 1999, pages 56 - 61, ISSN: 0002728401 *
PENG ET AL, GENOMICS, vol. 54, JPN6014001912, 1998, pages 529 - 541, ISSN: 0002728400 *
SHLIEN ET AL, PNAS, vol. 105, no. 32, JPN6014001918, 12 August 2008 (2008-08-12), pages 11264 - 11269, ISSN: 0002728402 *
STACEY SIMON N ET AL, NATURE GENETICS, vol. 39, no. 7, JPN5011006576, 1 July 2007 (2007-07-01), US, pages 865 - 869, ISSN: 0002728399 *
STACEY SIMON N ET AL: "COMMON VARIANTS ON CHROMOSOME 5P12 CONFER SUSCEPTIBILITY TO ESTROGEN RECEPTOR-POSITIVE BREAST CANCER", NATURE GENETICS, vol. 40, no. 6, JPN5011006574, 1 June 2008 (2008-06-01), US, pages 703 - 706, XP002491374, ISSN: 0002728397, DOI: 10.1038/ng.131 *
STEEMERS FRANK J ET AL: "WHOLE GENOME GENOTYPING TECHNOLOGIES ON THE BEADARRAY PLATFORM", BIOTECHNOLOGY JOURNAL, vol. 2, no. 1, JPN5011006571, January 2007 (2007-01-01), pages 41 - 49, XP002548190, ISSN: 0002728394, DOI: 10.1002/BIOT.200600213 *
THOMAS GILLES ET AL, NATURE GENETICS, vol. 41, no. 5, JPN5011006572, May 2009 (2009-05-01), pages 579 - 584, ISSN: 0002728395 *

Also Published As

Publication number Publication date
IL210504A0 (en) 2011-03-31
EP2313525A2 (en) 2011-04-27
AU2009269542A1 (en) 2010-01-14
US20110294673A1 (en) 2011-12-01
WO2010004591A2 (en) 2010-01-14
WO2010004591A3 (en) 2010-03-18
CA2729934A1 (en) 2010-01-14
CN102144036A (zh) 2011-08-03
KR20110036608A (ko) 2011-04-07
CN102144036B (zh) 2014-07-16
NZ590833A (en) 2013-01-25
US8951735B2 (en) 2015-02-10

Similar Documents

Publication Publication Date Title
JP5676245B2 (ja) 乳癌のリスクアセスメント、診断、予後診断および治療における使用のためのマーカーとしてのｃｈｒ２およびｃｈｒ１６の遺伝的変異
CN102144036B (zh) 用于乳腺癌风险评估的遗传变型
JP5631000B2 (ja) Ｃｈｒ８ｑ２４．２１上の癌感受性変異体
US8580501B2 (en) Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
CN102177252B (zh) 用于甲状腺癌症的风险评估的遗传变型
US8865400B2 (en) Genetic variants contributing to risk of prostate cancer
WO2013035114A1 (en) Tp53 genetic variants predictive of cancer
CN102137937A (zh) 作为用于膀胱癌风险评估、诊断、预后和治疗的标志的遗传变型
US20110020320A1 (en) Genetic Variants Contributing to Risk of Prostate Cancer
WO2013065072A1 (en) Risk variants of prostate cancer
EP2681337B1 (en) Brip1 variants associated with risk for cancer
WO2010131268A1 (en) Genetic variants for basal cell carcinoma, squamous cell carcinoma and cutaneous melanoma
WO2011095999A1 (en) Genetic variants for predicting risk of breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140414

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150630